These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 34012519)
1. Using CRISPR/Cas9 System to Knock out Exon 48 in Dara M; Razban V; Talebzadeh M; Moradi S; Dianatpour M Avicenna J Med Biotechnol; 2021; 13(2):54-57. PubMed ID: 34012519 [TBL] [Abstract][Full Text] [Related]
2. Dystrophin gene editing by CRISPR/Cas9 system in human skeletal muscle cell line (HSkMC). Dara M; Razban V; Mazloomrezaei M; Ranjbar M; Nourigorji M; Dianatpour M Iran J Basic Med Sci; 2021 Aug; 24(8):1153-1158. PubMed ID: 34804433 [TBL] [Abstract][Full Text] [Related]
3. A humanized knockin mouse model of Duchenne muscular dystrophy and its correction by CRISPR-Cas9 therapeutic gene editing. Zhang Y; Li H; Nishiyama T; McAnally JR; Sanchez-Ortiz E; Huang J; Mammen PPA; Bassel-Duby R; Olson EN Mol Ther Nucleic Acids; 2022 Sep; 29():525-537. PubMed ID: 36035749 [TBL] [Abstract][Full Text] [Related]
4. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing. Hanson B; Wood MJA; Roberts TC RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516 [TBL] [Abstract][Full Text] [Related]
5. Restoration of dystrophin expression and correction of Duchenne muscular dystrophy by genome editing. Aslesh T; Erkut E; Yokota T Expert Opin Biol Ther; 2021 Aug; 21(8):1049-1061. PubMed ID: 33401973 [No Abstract] [Full Text] [Related]
6. Targeting Duchenne muscular dystrophy by skipping DMD exon 45 with base editors. Gapinske M; Winter J; Swami D; Gapinske L; Woods WS; Shirguppe S; Miskalis A; Busza A; Joulani D; Kao CJ; Kostan K; Bigot A; Bashir R; Perez-Pinera P Mol Ther Nucleic Acids; 2023 Sep; 33():572-586. PubMed ID: 37637209 [TBL] [Abstract][Full Text] [Related]
7. Efficient Restoration of the Dystrophin Gene Reading Frame and Protein Structure in DMD Myoblasts Using the CinDel Method. Iyombe-Engembe JP; Ouellet DL; Barbeau X; Rousseau J; Chapdelaine P; Lagüe P; Tremblay JP Mol Ther Nucleic Acids; 2016 Jan; 5(1):e283. PubMed ID: 26812655 [TBL] [Abstract][Full Text] [Related]
8. The AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD. Wang JZ; Wu P; Shi ZM; Xu YL; Liu ZJ Brain Dev; 2017 Aug; 39(7):547-556. PubMed ID: 28390761 [TBL] [Abstract][Full Text] [Related]
9. Applications of CRISPR/Cas9 for the Treatment of Duchenne Muscular Dystrophy. Lim KRQ; Yoon C; Yokota T J Pers Med; 2018 Nov; 8(4):. PubMed ID: 30477208 [TBL] [Abstract][Full Text] [Related]
10. Prevention of early-onset cardiomyopathy in Rok M; Wong TWY; Maino E; Ahmed A; Yang G; Hyatt E; Lindsay K; Fatehi S; Marks R; Delgado-Olguín P; Ivakine EA; Cohn RD Mol Ther Methods Clin Dev; 2023 Sep; 30():246-258. PubMed ID: 37545481 [TBL] [Abstract][Full Text] [Related]
11. Creation of DMD Muscle Cell Model Using CRISPR-Cas9 Genome Editing to Test the Efficacy of Antisense-Mediated Exon Skipping. Maruyama R; Yokota T Methods Mol Biol; 2018; 1828():165-171. PubMed ID: 30171541 [TBL] [Abstract][Full Text] [Related]
12. Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR/Cas9 Gene Editing Therapy. Young CS; Mokhonova E; Quinonez M; Pyle AD; Spencer MJ J Neuromuscul Dis; 2017; 4(2):139-145. PubMed ID: 28505980 [TBL] [Abstract][Full Text] [Related]
13. A novel human muscle cell model of Duchenne muscular dystrophy created by CRISPR/Cas9 and evaluation of antisense-mediated exon skipping. Shimo T; Hosoki K; Nakatsuji Y; Yokota T; Obika S J Hum Genet; 2018 Mar; 63(3):365-375. PubMed ID: 29339778 [TBL] [Abstract][Full Text] [Related]
14. Correction of DMD in human iPSC-derived cardiomyocytes by base-editing-induced exon skipping. Wang P; Li H; Zhu M; Han RY; Guo S; Han R Mol Ther Methods Clin Dev; 2023 Mar; 28():40-50. PubMed ID: 36588820 [TBL] [Abstract][Full Text] [Related]
15. A consolidated AAV system for single-cut CRISPR correction of a common Duchenne muscular dystrophy mutation. Zhang Y; Nishiyama T; Li H; Huang J; Atmanli A; Sanchez-Ortiz E; Wang Z; Mireault AA; Mammen PPA; Bassel-Duby R; Olson EN Mol Ther Methods Clin Dev; 2021 Sep; 22():122-132. PubMed ID: 34485599 [TBL] [Abstract][Full Text] [Related]
16. Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy. Amoasii L; Long C; Li H; Mireault AA; Shelton JM; Sanchez-Ortiz E; McAnally JR; Bhattacharyya S; Schmidt F; Grimm D; Hauschka SD; Bassel-Duby R; Olson EN Sci Transl Med; 2017 Nov; 9(418):. PubMed ID: 29187645 [TBL] [Abstract][Full Text] [Related]
17. Promising therapeutic approaches using CRISPR/Cas9 genome editing technology in the treatment of Duchenne muscular dystrophy. Mollanoori H; Rahmati Y; Hassani B; Havasi Mehr M; Teimourian S Genes Dis; 2021 Mar; 8(2):146-156. PubMed ID: 33997161 [TBL] [Abstract][Full Text] [Related]
18. CRISPR Therapeutics for Duchenne Muscular Dystrophy. Erkut E; Yokota T Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163754 [TBL] [Abstract][Full Text] [Related]
19. Cellular Reprogramming, Genome Editing, and Alternative CRISPR Cas9 Technologies for Precise Gene Therapy of Duchenne Muscular Dystrophy. Gee P; Xu H; Hotta A Stem Cells Int; 2017; 2017():8765154. PubMed ID: 28607562 [TBL] [Abstract][Full Text] [Related]
20. Functional Rescue of Dystrophin Deficiency in Mice Caused by Frameshift Mutations Using Campylobacter jejuni Cas9. Koo T; Lu-Nguyen NB; Malerba A; Kim E; Kim D; Cappellari O; Cho HY; Dickson G; Popplewell L; Kim JS Mol Ther; 2018 Jun; 26(6):1529-1538. PubMed ID: 29730196 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]